Hormonal therapy with a levonorgestrel-releasing intrauterine device (LNG-IUD) led to a high pathological complete response (pCR) rate in women with early-stage endometrial cancer, according to the feMMe trial presented at SGO 2021 Meeting.
The addition of the oral, small-molecule tyrosine kinase inhibitor apatinib to pegylated liposomal doxorubicin (PLD) led to a significant improvement in progression-free survival (PFS) among women with platinum-resistant or refractory recurrent ovarian cancer* compared with PLD alone, according to the results of the APPROVE trial presented at SGO 2021.
Maintenance treatment with olaparib showed progression-free survival (PFS) benefit in patients with platinum-sensitive relapsed ovarian cancer (PSR OC), particularly those with somatic BRCA mutation (BRCAm), according to results of the ORZORA* trial presented at SGO 2021.
In patients with advanced endometrial cancer with prior platinum chemotherapy exposure, a combination of lenvatinib + pembrolizumab improved survival compared with physician’s choice of treatment (TPC), results of the phase III Study 309/KEYNOTE-775 trial showed.
In women with newly diagnosed, advanced* ovarian cancer and a BRCA mutation**, the progression-free survival (PFS) benefit with maintenance olaparib was sustained beyond end of treatment, according to the 5-year follow-up results of the SOLO1 trial presented at SGO 2021.
The PARP inhibitor rucaparib significantly improves progression-free survival (PFS) in patients with recurrent, advanced BRCA-positive ovarian cancer compared with standard-of-care chemotherapy, according to the ARIEL4 study presented at the SGO 2021 Meeting.
Maintenance treatment with fuzuloparib resulted in significantly improved progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer, according to a study presented at SGO 2021.
Women with early-stage cervical cancer who conceive ≥3 months following fertility-sparing surgery may be at an increased risk of preterm delivery, according to results of a retrospective study presented at SGO 2021.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
In a webinar held on 27 March 2021, paediatric
endocrinology nurses Karen Blair,
Kate Davies, and Siti Zarina Yaakop shared
insights and clinical experience based
on their frontline roles in caring for patients
with central precocious puberty (CPP)
and supporting their family members.